Brief: Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
03/01/2024 12:34
Jan 3 (Reuters) - Apollomics Inc APLM.O :
* APOLLOMICS COMPLETES ENROLLMENT IN PHASE 3 BRIDGING STUDY
OF
UPROLESELAN IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY ACUTE
MYELOID LEUKEMIA
* APOLLOMICS INC: PRIMARY ENDPOINT FOR PHASE 3 BRIDGING
STUDY IS
OVERALL SURVIVAL
Source text for Eikon: ID:nGNX4j48wd
Further company coverage: APLM.O
((Reuters.Briefs@thomsonreuters.com;))